Atara biotherapeutics presents updated clinical data from pivotal phase 3 trial (allele) of tab-cel® at the 64th american society of hematology (ash) annual meeting

Thousand oaks, calif.--( business wire )--atara biotherapeutics, inc. (nasdaq: atra), a leader in t-cell immunotherapy, leveraging its novel allogeneic epstein-barr virus (ebv) t-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced updated interim analysis and safety results from its phase 3 multicenter allele study investigating tabelecleucel (tab-cel®) for the treatment of relapsed/refractory (r/r) epstein-barr virus positive post-transplant lymphoproliferative disease (ebv+ ptld) following solid organ transplant (sot) or hematopoietic cell transplant (hct).
ATRA Ratings Summary
ATRA Quant Ranking